Impax Laboratories (IPXL) Story Intact Despite Bruising
Tweet Send to a Friend
Canaccord Genuity reiterated a Buy rating on Impax Laboratories (NASDAQ: IPXL) but trimmed its price target to $27.00 (from $29.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


